Shenzhen and Hong Kong have drawn up a new blueprint for cross-border medical care - -Our company and Hong Kong Medical Authority visited Nanshan Hospital and Peking University Shenzhen Hospital for e
On September 27th, Dr. Xiang Hua, director, co-founder and deputy general manager of Shenzhen Cell Valley, and Ms.Sun Rui, joined hands with Dr. Su Jieying team, director of Hong Kong Hospital Administration and Hong Kong Island East Hospital to Shenzhen Nanshan District People's Hospital (hereinafter referred to as; Nanshan Hospital) and Peking University Shenzhen Hospital (hereinafter referred to as: Peking University Shenzhen Hospital) for an exchange visit. This visit aims to make full use of the unique advantages of our company as a supply platform for cell therapy products, and work with the medical institutions of cutting-edge technology in Hong Kong and Shenzhen to promote the clinical research and practical application of cell products.
Symposium photo of Shenzhen Nanshan District People's Hospital
At the symposium held in Nanshan Hospital, Vice President Liu Yansong, Section Chief Chen Chuanhuang of the Science and Education Department and Director Guo Zhi of the Department of Hematology all extended warm welcome to the guests from Shenzhen and Hong Kong. During the meeting, the three parties held in-depth discussions on the current international development trend of cell and gene therapy and the potential opportunities of future Shenzhen-Hong Kong cooperation. In addition, Wang Qiang, dean of the Medical Science Department of Wuhan University of Science and Technology, attended the meeting online. He and Professor Guo Zhi gave a detailed introduction to the IIT research projects of several centers led by the school, providing valuable research information and experience sharing for the cooperation.
Symposium photo of Peking University Shenzhen Hospital
At the symposium of Peking University Shenzhen Hospital, Vice President Zhao Yongsheng, Director Shi Yu of Scientific Research and Teaching Department, Director Zhang Hongyu, Director of Hematology Department, Director Chen Junhui of Interventional Department and other expert teams gathered together. At the meeting, the Hong Kong Medical Authority team formally introduced the network of Hong Kong Island East Hospital. As the largest hospital network in Hong Kong, it has a wide range of jurisdiction, including seven public hospitals, seven specialized outpatient clinics and 12 general outpatient clinics. The hospital network is not only committed to providing comprehensive and professional medical services, but also shoulders the important mission of promoting the innovation and development of smart hospital services. Subsequently, our company shared the latest research results and clinical application cases of Shenzhen Cell Valley in the field of cell therapy. In particular, we have emphasized the independent development and successful series of non-modified allogeneic NK cell therapy products, as well as a variety of CAR T cell products using advanced retroviral vector technology, which have achieved significant breakthroughs. At present, the above product series has established deep cooperative relations with a number of medical institutions, and has been practical efficacy and verified in clinical practice.
At the end of the symposium, the three parties exchanged views on clinical application experience of cell therapy and patient management strategies, and discussed potential cooperation opportunities in scientific research cooperation, talent training, technology transformation and other aspects.
The our joint visit with Hong Kong hospital authority, not only deepen the understanding and trust between the two sides, Hong Kong also with two hospitals in-depth communication and learning, focusing on cell therapy products clinical application process, patient management strategy and treatment measures, in order to further enhance the safety and effectiveness of clinical application. We firmly believe that with the joint efforts of Shenzhen and Hong Kong, we will strongly promote the coordinated development of the two places in the field of cell therapy and provide better quality and efficient medical services to the residents of both places.
Symposium photo of Shenzhen Nanshan District People's Hospital
Symposium photo of Peking University Shenzhen Hospital
At the end of the symposium, the three parties exchanged views on clinical application experience of cell therapy and patient management strategies, and discussed potential cooperation opportunities in scientific research cooperation, talent training, technology transformation and other aspects.
The our joint visit with Hong Kong hospital authority, not only deepen the understanding and trust between the two sides, Hong Kong also with two hospitals in-depth communication and learning, focusing on cell therapy products clinical application process, patient management strategy and treatment measures, in order to further enhance the safety and effectiveness of clinical application. We firmly believe that with the joint efforts of Shenzhen and Hong Kong, we will strongly promote the coordinated development of the two places in the field of cell therapy and provide better quality and efficient medical services to the residents of both places.
